{"disease":{"id":"sclerosis","name":"sclerosis"},"drugs":{"marketed":[{"drug_id":"ocrelizumab","indication_name":"Primary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocrevus","generic_name":"OCRELIZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":"6500","mechanism":"Ocrevus works by binding to the CD20 protein on B cells, marking them for destruction and reducing their ability to contribute to the disease process."},{"drug_id":"rituxan","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"humax-cd20","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arzerra","generic_name":"HuMax-CD20","company_name":"Glaxo Grp Ltd","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":null,"revenue":"3198","mechanism":"Arzerra works by binding to the CD20 protein on B cells, marking them for destruction by the immune system."},{"drug_id":"humax-cd20","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arzerra","generic_name":"HuMax-CD20","company_name":"Glaxo Grp Ltd","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":null,"revenue":"3198","mechanism":"Arzerra works by binding to the CD20 protein on B cells, marking them for destruction by the immune system."},{"drug_id":"dimethyl-fumarate","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecfidera","generic_name":"DIMETHYL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"dimethyl fumarate","quality_score":59,"revenue":"2800","mechanism":"Tecfidera works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation and modulate the immune system."},{"drug_id":"nintedanib","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ofev","generic_name":"NINTEDANIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2000","mechanism":"Ofev works by blocking enzymes that promote fibrosis and tumor growth."},{"drug_id":"natalizumab","indication_name":"Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tysabri","generic_name":"NATALIZUMAB","company_name":"Biogen Idec","drug_phase":"marketed","molecular_target":"α4β1 and α4β7 integrins","drug_class":"Integrin Receptor Antagonist [EPC]","quality_score":70,"revenue":"1600","mechanism":"Natalizumab blocks α4 integrins on leukocytes, preventing their adhesion to VCAM-1 and MAdCAM-1, reducing inflammation in MS and Crohn's disease."},{"drug_id":"natalizumab","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tysabri","generic_name":"NATALIZUMAB","company_name":"Biogen Idec","drug_phase":"marketed","molecular_target":"α4β1 and α4β7 integrins","drug_class":"Integrin Receptor Antagonist [EPC]","quality_score":70,"revenue":"1600","mechanism":"Natalizumab blocks α4 integrins on leukocytes, preventing their adhesion to VCAM-1 and MAdCAM-1, reducing inflammation in MS and Crohn's disease."},{"drug_id":"teriflunomide","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aubagio","generic_name":"TERIFLUNOMIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"dihydroorotate dehydrogenase","drug_class":"Pyrimidine Synthesis Inhibitor [EPC]","quality_score":75,"revenue":"1100","mechanism":"Teriflunomide inhibits dihydroorotate dehydrogenase, reducing activated lymphocytes in the CNS."},{"drug_id":"teriflunomide","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aubagio","generic_name":"TERIFLUNOMIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"dihydroorotate dehydrogenase","drug_class":"Pyrimidine Synthesis Inhibitor [EPC]","quality_score":75,"revenue":"1100","mechanism":"Teriflunomide inhibits dihydroorotate dehydrogenase, reducing activated lymphocytes in the CNS."},{"drug_id":"siponimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mayzent","generic_name":"SIPONIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator [EPC]","quality_score":10,"revenue":"1068","mechanism":"Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"siponimod","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mayzent","generic_name":"SIPONIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator [EPC]","quality_score":10,"revenue":"1068","mechanism":"Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"alirocumab","indication_name":"Atherosclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praluent","generic_name":"ALIROCUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":62,"revenue":"857","mechanism":"Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels."},{"drug_id":"ozanimod","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zeposia","generic_name":"OZANIMOD","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":72,"revenue":"800","mechanism":"Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"interferon-beta-1a","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avonex","generic_name":"INTERFERON BETA-1A","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":55,"revenue":"800","mechanism":"Avonex works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"ozanimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zeposia","generic_name":"OZANIMOD","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":72,"revenue":"800","mechanism":"Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"peginterferon-beta-1a","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plegridy","generic_name":"PEGINTERFERON BETA-1A","company_name":"Biogen Idec Inc","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":"800","mechanism":"Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"glatiramer-acetate","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Copaxone","generic_name":"GLATIRAMER ACETATE","company_name":"Teva","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":"700","mechanism":"Copaxone works by modulating the immune system's response to reduce inflammation in the central nervous system."},{"drug_id":"cladribine","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leustatin","generic_name":"CLADRIBINE","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","drug_class":"Purine Antimetabolite [EPC]","quality_score":75,"revenue":"700","mechanism":"Leustatin works by inhibiting the enzyme that breaks down cyclic adenosine monophosphate (cAMP), leading to an accumulation of cAMP and subsequent activation of various cellular pathways."},{"drug_id":"everolimus","indication_name":"Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"everolimus","indication_name":"Tuberous sclerosis syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"diroximel-fumarate","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"diroximel-fumarate","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"fampridine","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"fampridine","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Voltage-gated potassium channel, Potassium voltage-gated channel subfamily C member 1, Potassium voltage-gated channel subfamily C member 2","drug_class":"","quality_score":27,"revenue":"400","mechanism":null},{"drug_id":"tofersen","indication_name":"Amyotrophic lateral sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qalsody","generic_name":"TOFERSEN","company_name":"Biogen Ma","drug_phase":"marketed","molecular_target":"Superoxide dismutase 1 (SOD1) mRNA","drug_class":"Antisense Oligonucleotide [EPC]","quality_score":10,"revenue":"200","mechanism":"Qalsody works by binding to the messenger RNA (mRNA) of the Superoxide dismutase 1 (SOD1) gene, preventing its expression and reducing the production of the toxic SOD1 protein associated with ALS."},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"triamcinolone","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vumerity","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vumerity","company_name":"University of Nebraska","drug_phase":"marketed","molecular_target":"Nuclear factor erythroid 2-related factor 2, Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"fampyra","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fampyra","company_name":"Vestre Viken Hospital Trust","drug_phase":"phase_2","molecular_target":"Voltage-gated potassium channel, Potassium voltage-gated channel subfamily C member 1, Potassium voltage-gated channel subfamily C member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ofev","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OFEV®","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"Kinase Inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"fingolimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gilenya","generic_name":"FINGOLIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":75,"revenue":null,"mechanism":"Gilenya works by binding to and blocking the S1P1 receptor, preventing immune cells from leaving the lymph nodes and reducing inflammation in the central nervous system."},{"drug_id":"neurontin","indication_name":"Seizures associated with amyotrophic lateral sclerosis (ALS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"ruxience","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"alemtuzumab","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."},{"drug_id":"fty720","indication_name":"Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FTY720","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)","drug_class":"Sphingosine-1-phosphate receptor modulator; Immunomodulator","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"sirolimus","indication_name":"Tuberous sclerosis syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapamune","generic_name":"sirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"mTOR Inhibitor Immunosuppressant [EPC]","quality_score":80,"revenue":null,"mechanism":"Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells."},{"drug_id":"daclizumab","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zenapax","generic_name":"DACLIZUMAB","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Interleukin-2 Receptor Blocking Antibody","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"buphenyl","indication_name":"Amyotrophic lateral sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Buphenyl","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Aldose reductase, Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tysabri","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tysabri","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Integrin alpha-4/beta-1, Integrin alpha-4/beta-7","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Acute exacerbations of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"avonex","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avonex","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gilenya","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gilenya","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate lyase 1, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"plegridy","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Plegridy","company_name":"Holy Name Medical Center, Inc.","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"arzerra","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arzerra","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"arzerra","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arzerra","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"vargatef","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vargatef","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"discontinued","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"betaseron","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Betaseron","company_name":"University of Medicine and Dentistry of New Jersey","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rapamycin","indication_name":"Tuberous sclerosis syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamycin","company_name":"Institut National de la Santé Et de la Recherche Médicale, France","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tecfidera","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tecfidera","company_name":"EMD Serono Research & Development Institute, Inc.","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2, Kelch-like ECH-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zenapax","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zenapax","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"phase_3","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mitozantrone","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taurursodiol","indication_name":"Amyotrophic lateral sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Relyvrio","generic_name":"TAURURSODIOL","company_name":"Amylyx","drug_phase":"marketed","molecular_target":"Phospholipase A2","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Relyvrio works by inhibiting the enzyme phospholipase A2, which is involved in the breakdown of lipids in the brain."},{"drug_id":"radicava","indication_name":"Amyotrophic lateral sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Radicava","company_name":"Shanghai Auzone Biological Technology Co., Ltd.","drug_phase":"marketed","molecular_target":"Polyunsaturated fatty acid lipoxygenase ALOX15","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone-phosphate","indication_name":"Acute exacerbations of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"natalizumab-sztn","indication_name":"Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TYRUKO","generic_name":"NATALIZUMAB-SZTN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Integrin Receptor Antagonist [EPC]","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"mitoxantrone","indication_name":"Multiple Sclerosis - Secondary Progressive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"mitoxantrone","indication_name":"Multiple Sclerosis - Progressive Relapsing","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"mitoxantrone","indication_name":"Multiple Sclerosis - Worsening Relapsing-Remitting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"chembl-chembl1496","indication_name":"Reduce LDL-C and slow atherosclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ROSUVASTATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"fingolimod-hydrochloride","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FINGOLIMOD HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"sativex","indication_name":"Muscle Spasticity due to Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sativex","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"aminobenzoic-acid","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aminobenzoate Potassium","generic_name":"aminobenzoic acid","company_name":"","drug_phase":"unknown","molecular_target":"Carbonic anhydrase 2","drug_class":"Vitamin B Complex Member","quality_score":null,"revenue":null,"mechanism":"Aminobenzoate Potassium works by inhibiting the enzyme carbonic anhydrase 2, which plays a crucial role in maintaining the pH balance in cells."},{"drug_id":"benzoic-acid","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzeneformic Acid","generic_name":"benzoic acid","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"laquinimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nerventra","generic_name":"LAQUINIMOD","company_name":"Teva","drug_phase":"discontinued","molecular_target":"","drug_class":"laquinimod","quality_score":null,"revenue":null,"mechanism":"Nerventra works by modulating the immune system to reduce inflammation in the central nervous system."},{"drug_id":"rapamune","indication_name":"Tuberous sclerosis syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamune","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"hydrocortisone-succinate","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"edaravone","indication_name":"Amyotrophic lateral sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Radicava","generic_name":"EDARAVONE","company_name":"Kk Bcj-94","drug_phase":"marketed","molecular_target":"","drug_class":"edaravone","quality_score":51,"revenue":null,"mechanism":"Radicava works by scavenging free radicals and reducing oxidative stress in the body."},{"drug_id":"azathioprine","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"corticotropin","indication_name":"Exacerbation of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acthar Gel","generic_name":"CORTICOTROPIN","company_name":"Mallinckrodt Ireland","drug_phase":"marketed","molecular_target":"Melanocyte-stimulating hormone receptor","drug_class":"Adrenocorticotropic Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"bosentan","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tracleer","generic_name":"BOSENTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"riluzole","indication_name":"Amyotrophic lateral sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rilutek","generic_name":"RILUZOLE","company_name":"Covis","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Benzothiazole [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of chronic pain associated with adult patients with multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"colchicine","indication_name":"Atherosclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Colcrys","generic_name":"COLCHICINE","company_name":"Scilex Pharms","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Alkaloid [EPC]","quality_score":10,"revenue":null,"mechanism":"Colcrys works by inhibiting the activity of a specific enzyme called serine/threonine-protein kinase pim-1."},{"drug_id":"mayzent","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mayzent","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"mayzent","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mayzent","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"riltozinameran-12-years-of-age-and-older","indication_name":"Amyotrophic lateral sclerosis (ALS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riltozinameran 12 Years of age and older","generic_name":"riltozinameran-12-years-of-age-and-older","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":34,"revenue":null,"mechanism":"Mechanism of action is not specified on Wikipedia."},{"drug_id":"campath","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"afinitor","indication_name":"Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"afinitor","indication_name":"Tuberous sclerosis syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cannabinoids","indication_name":"Muscle Spasticity due to Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cannabinoids","company_name":"New York State Psychiatric Institute","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ocrevus","indication_name":"Primary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ocrevus","company_name":"Kessler Foundation","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"praluent","indication_name":"Atherosclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Praluent","company_name":"Regeneron Pharmaceuticals","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"interferon-beta-1b","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaseron","generic_name":"INTERFERON BETA-1B","company_name":"Bayer Healthcare Pharms","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta","quality_score":10,"revenue":null,"mechanism":"Betaseron works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"copaxone","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Copaxone","company_name":"University of California, Los Angeles","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"orthocaine","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"orthocaine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ublituximab-xiiy","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BRIUMVI","generic_name":"UBLITUXIMAB-XIIY","company_name":"TG THERAPEUTICS, INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"pf-06700841","indication_name":"Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06700841","generic_name":"pf-06700841","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"pf-06700841-45-mg","indication_name":"Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06700841 45 mg","generic_name":"pf-06700841-45-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown target","drug_class":"Unknown class","quality_score":56,"revenue":null,"mechanism":"Unknown mechanism of action"},{"drug_id":"hydrocortisone","indication_name":"Multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mitoxantrone","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."}],"pipeline":[{"drug_id":"cromolyn-sodium","indication_name":"Amyotrophic Lateral Sclerosis (ALS)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CROMOLYN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Mast cells","drug_class":"Mast cell stabilizer","quality_score":30,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":121,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06406998","title":"Maternal and Offspring Outcomes in Pregnant Women With Pre-existing ASCVD","phase":"","overall_status":"RECRUITING","enrollment_count":5461222,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05796037","title":"An Observational Study of Patients Living With Chronic Neurological Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500000,"lead_sponsor_name":"Target PharmaSolutions, Inc.","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT03456206","title":"Chronic Inflammatory Disease, Lifestyle and Risk of Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":57053,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT06794684","title":"PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06856772","title":"Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":42000,"lead_sponsor_name":"Tor Biering-Sørensen","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04505098","title":"A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":39600,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT04472975","title":"Prescription Drug Safety and Effectiveness in Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":35000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT04353232","title":"Impact of Lifetime Exposure to Air and Noise Pollution on Cardiovascular Disease and Mortality - the AIRCARD Study.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33723,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT05932472","title":"Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":32706,"lead_sponsor_name":"Tor Biering-Sørensen","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05437107","title":"Mechanism and Intervention Research of Atherosclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":30000,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT00526474","title":"Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":26449,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06933745","title":"Ultrasound Assessment of Atherosclerotic Plaque Burden and Cardiovascular Risk: A 10-Year Prospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":21029,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT05762003","title":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":17478,"lead_sponsor_name":"IMPULS Endowment Fund","has_results":false},{"nct_id":"NCT03228459","title":"The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16660,"lead_sponsor_name":"Institut de Recerca Biomèdica de Lleida","has_results":false},{"nct_id":"NCT00799903","title":"The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15828,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06008756","title":"Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14550,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04863586","title":"COVID-19 and Multiple Sclerosis Disease Modifying Therapies","phase":"","overall_status":"UNKNOWN","enrollment_count":14240,"lead_sponsor_name":"Nottingham University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT03799185","title":"Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population","phase":"","overall_status":"COMPLETED","enrollment_count":13610,"lead_sponsor_name":"Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose","has_results":false},{"nct_id":"NCT05542719","title":"Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular","phase":"","overall_status":"UNKNOWN","enrollment_count":13166,"lead_sponsor_name":"Coordinación de Investigación en Salud, Mexico","has_results":false},{"nct_id":"NCT06855394","title":"Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13000,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT00527943","title":"Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":12944,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05767736","title":"A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10500,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT01327846","title":"Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":10066,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT07080151","title":"Zhongshan Hospital Cardiovascular Imaging Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT06253481","title":"Genetics of Cardiovascular Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Center for Strategic Planning, of the Federal Medical and Biological Agency","has_results":false},{"nct_id":"NCT06643858","title":"Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT05154370","title":"China National Registry of Neuro-Inflammatory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04114994","title":"Longitudinal Cognitive Assessment by BoCA","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Alzheimer's Light LLC","has_results":false},{"nct_id":"NCT05605782","title":"A Post-Authorization, Long-term Study of Ozanimod Real-world Safety","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9000,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04624854","title":"Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":8250,"lead_sponsor_name":"Harbin Medical University","has_results":false},{"nct_id":"NCT06221618","title":"Evaluation of Vascular Structure in Elderly Using High-frequency Ultrasound and Construction of a Multimodal Risk Assessment System for Cardiovascular Diseases: a Multicenter Study","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT02915198","title":"Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":7410,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06443333","title":"National, Multicentric Registry Study on Neuroimmunological Diseases in China","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT01585298","title":"STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":6998,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT00493298","title":"Tysabri Observational Program","phase":"","overall_status":"COMPLETED","enrollment_count":6620,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06327984","title":"Barts Sex-CAD Database - Sex Hormones and Inflammatory Status in Coronary Artery Disease","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT03746275","title":"Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid","phase":"","overall_status":"COMPLETED","enrollment_count":5798,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01322568","title":"Research on Aging Project in Iceland: Second Stage","phase":"","overall_status":"COMPLETED","enrollment_count":5764,"lead_sponsor_name":"National Institute on Aging (NIA)","has_results":false},{"nct_id":"NCT02047097","title":"Dimethyl Fumarate (DMF) Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":5487,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06854341","title":"A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data","phase":"","overall_status":"COMPLETED","enrollment_count":5448,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00005485","title":"The Jackson Heart Study of Cardiovascular Disease Among African Americans","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5306,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}